Shares of Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSE:I) dropped 6.1% during trading on Wednesday . The stock traded as low as $1.01 and last traded at $1.08. Approximately 1,342,861 shares changed hands during trading, an increase of 215% from the average daily volume of 426,209 shares. The stock had previously closed at $1.15.

IPCI has been the topic of several research analyst reports. Maxim Group decreased their target price on Intellipharmaceutics International from $6.00 to $2.00 and set a “buy” rating on the stock in a report on Thursday, July 27th. Mackie upgraded Intellipharmaceutics International to a “hold” rating and increased their target price for the stock from $1.00 to $3.10 in a report on Tuesday, September 26th. Zacks Investment Research upgraded Intellipharmaceutics International from a “sell” rating to a “hold” rating in a report on Tuesday, August 15th. Finally, ValuEngine cut Intellipharmaceutics International from a “hold” rating to a “sell” rating in a report on Friday, July 28th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $3.78.

The stock’s market cap is $33.02 million. The stock’s 50-day moving average is $0.99 and its 200 day moving average is $1.76.

An institutional investor recently raised its position in Intellipharmaceutics International stock. Advisor Group Inc. increased its position in shares of Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSE:I) by 57.7% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 47,409 shares of the company’s stock after acquiring an additional 17,342 shares during the period. Advisor Group Inc. owned about 0.16% of Intellipharmaceutics International worth $100,000 at the end of the most recent reporting period. 4.24% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Intellipharmaceutics International Inc. (IPCI) Stock Price Down 6.1%” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece can be read at

Intellipharmaceutics International Company Profile

Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.

Receive News & Stock Ratings for Intellipharmaceutics International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellipharmaceutics International Inc. and related stocks with our FREE daily email newsletter.